Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652 | Completed Phase 1 DMC

• 1 other identifier: GCO 13-1390
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

The study is designed to see if a course of injections containing the NY-ESO-1 protein (a tumor antigen, marker expressed by tumors); in combination with an immune stimulant (adjuvant) Montanide, with or without resiquimod (another adjuvant) is well tolerated and safe in patients with surgically resected Stage IIB, IIC, Stage III or Stage IV (AJCC criteria) melanoma, a tumor that expresses NY-ESO-1. In addition, this study is designed to see if the patient's body's defense (immune) system can be boosted (strengthened) by this vaccine and if the addition of resiquimod to the vaccine makes this more likely.

Conditions

Tumors

Keywords

Tumor; NY-ESO-1 expression; Tumors that often express NY-ESO-1.

Outcome Measures

Primary Outcomes (1)

• The primary objectives of the study are to define the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide® ISA-51 VG when given with or without the topical TLR 7/8 agonist resiquimod.

  Blood samples are obtained at baseline, 1 week after each vaccination, and at follow-up 1visit.

Secondary Outcomes (1)

• To document tumor response by RECIST criteria if applicable. Skin section analysis of resiquimod/placebo treated site for immune cell infiltration and gene expression analysis. Investigation of polymorphisms for TLR7/8 through germline SNP analysis

  Skin biopsies will be obtained after the last vaccination cycle. Clinical hematology and biochemistry measurements will be taken at baseline, one week after the second vaccination and two to four weeks after the fourth vaccination

Study Arms (2)

Dose-esclation

OTHER

Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.

Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod

2

EXPERIMENTAL

Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.

Drug: NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo

Interventions

NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod DRUG

Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.

Dose-esclation

NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo DRUG

Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.

2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients will be eligible for enrollment if they fulfill the following criteria:
• Histological diagnosis of surgically resected Stage IIB, IIC, Stage III or Stage IV (AJCC criteria) melanoma independent of NY-ESO-1 expression in a tumor biopsy
• At least 4 weeks since surgery prior to first dosing of study agent.
• Laboratory values within the following limits:
• Hemoglobin \> 10.0 g/dL Neutrophil count \> 1.5 x l09/L Lymphocyte count \> Lower limit of institutional normal Platelet count \> 80 x l09/L Serum creatinine \< 2.0 mg/dL Serum bilirubin \< 2 x upper limit of institutional normal AST/ALT \< 2 x upper limit of institutional normal
• Patients must have an ECOG performance status of \<2 (ECOG criteria published in \[46\])
• Life expectancy \> 6 months.
• Age \> 18 years.
• Able and willing to give written informed consent for participation in the trial (see Section 12.2)
• Patients enrolled in the adjuvant setting must have received standard curative therapy, e.g., surgery, radiation. Alternatively, patients can enter after refusing standard curative therapy only if therapy was clearly discussed with the treating physician or if they have failed another biologic therapy due to toxicity.

You may not qualify if:

• Patients will be excluded from the study if they fulfill any of the following criteria:
• Serious illnesses, e.g., serious infections requiring antibiotics.
• Previous bone marrow or stem cell transplant.
• History of immunodeficiency disease (such as HIV) or autoimmune disease except vitiligo.
• Metastatic disease to the central nervous system.
• Other malignancy prior to entry into the study.
• No radiation therapy, prior biological therapy or surgery within 4 weeks prior to first dose of study agent.
• No prior chemotherapy or prior vaccine or immunotherapy.
• Concomitant treatment with systemic corticosteroids greater than physiologic doses. Topical (but not at the proposed vaccination sites) or inhalational steroids are permitted. (See also Section 6.7 for restrictions/recommendations on 'Ancillary Therapy'.)
• Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.
• Pregnancy or lactation.
• Women of childbearing potential not using a medically acceptable means of contraception.
• Patients with known history of inflammatory skin disorders (e.g.,psoriasis, lupus) that may be exacerbated by Resiquimod.
• Psychiatric or addictive disorders that may compromise the ability to give informed consent.
• Lack of availability of the patient for immunological and clinical follow-up assessment.

Sponsors & Collaborators

• Nina Bhardwaj: lead
• Cancer Research Institute, New York City: collaborator

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

resiquimod

Study Officials

• Nina Bhardwaj, MD, PhD

  Icahn School of Medicine at Mount Sinai

  PRINCIPAL INVESTIGATOR

• Rachel Sabado, PhD

  Icahn School of Medicine at Mount Sinai

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director, Immunotherapy Program

Study Record Dates

• First Submitted: January 12, 2009
• First Posted: January 13, 2009
• Study Start: February 1, 2009
• Primary Completion: January 1, 2010
• Study Completion: December 1, 2014
• Last Updated: January 8, 2015

Record last verified: 2014-12

Locations

US (1)